Doxorubicin alters the disposition of phenytoin by reducing its metabolic elimination and binding affinity to serum albumin in rats.

Shuhei Fukuno Katsuhito NagaiShizuka YamaokaFuka YamadaHaruna MizumotoTakuya Ito Hiroki Konishi

Published in: The Journal of pharmacy and pharmacology (2022)

DOX treatment increases the unbound serum PHT concentration by depressing the metabolic capacity and alters the total PHT by reducing serum albumin and its affinity to PHT.

Keyphrases

drug delivery
capillary electrophoresis
cancer therapy
transcription factor
replacement therapy